Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 7Lymphoma, Non-Hodgkin 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hodgkin Disease 5Multiple Myeloma 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Anemia, Refractory, with Excess of Blasts 4Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Accelerated Phase 3Leukemia 3Colorectal Neoplasms 3Burkitt Lymphoma 3Stomach Neoplasms 2Sarcoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Neoplasm, Residual 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Melanoma 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelomonocytic, Juvenile 2

Interventions

asciminib 2venetoclax 1gilteritinib 1fludarabine phosphate 1fludarabine 1blinatumomab 1N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Idarubicin 1Hyperbaric Oxygenation 1Filgrastim 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid × fludarabine phosphate × 30 days × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡